NCT02303509 - Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

Psoriasis

Interventions

DRUG

UCB5857 Part 1

"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 1 mg, 5 mg, 10 mg or 15 mg~Route of administration: Oral"

DRUG

UCB5857 Part 2

"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 5 mg, 8 mg, 15 mg~Route of administration: Oral"

OTHER

Placebo

"Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral"

Trial Locations (1)

001, Harrow